Nanog shRNA Viral Vector for Colorectal Cancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for colorectal carcinoma (CRC) lack effective therapeutics to prevent and treat the disease, with Nanog and its pseudogene, NanogP8, playing a crucial role in cancer stem cell maintenance and resistance to chemotherapy, necessitating a targeted approach to inhibit their expression.
Innovation Solution
Development of a pharmaceutical composition comprising an oligonucleotide that selectively knocks down expression of either Nanog or NanogP8 using a viral vector, such as a lentivirus or adenovirus, to inhibit cancer cell proliferation and induce apoptosis, specifically designed to target colorectal cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for colorectal carcinoma are used, then treatment is provided, but effective therapeutics to prevent and treat the disease are lacking
Solution Approach 1:
The patent extracts and targets specific molecular components (Nanog and NanogP8 pseudogene) that are critical for cancer stem cell maintenance. By isolating and suppressing these specific targets using shRNA vectors, the invention achieves effective therapy where conventional treatments fail, directly addressing the lack of effective therapeutics for CRC.
Solution Approach 2:
The patent changes the molecular parameter expression by silencing Nanog and NanogP8 through RNA interference. This parameter change in gene expression translates to reduced cancer stem cell proliferation and increased apoptosis, providing effective therapeutic action against colorectal carcinoma.
2Reliability
If Nanog and NanogP8 are inhibited, then cancer cell growth is suppressed, but selective targeting is required to avoid affecting normal cells
Solution Approach 1:
The patent segments the targeting approach by designing separate shRNA constructs specific for Nanog and NanogP8. This segmentation allows independent optimization of each target's specificity, ensuring that normal cells expressing Nanog are not affected while cancer stem cells with NanogP8 are selectively eliminated.
Solution Approach 2:
The invention applies local quality by creating cell-type specific targeting. The shRNA vectors are designed to preferentially express in cancer stem cells based on their unique expression profile of NanogP8, while sparing normal intestinal cells that do not express NanogP8, thus achieving selective suppression without harmful off-target effects.
3Reliability
If viral vectors are used to deliver shRNA, then efficient gene silencing is achieved, but vector safety and replication control must be maintained
Solution Approach 1:
The patent converts the potential harm of viral vector replication into a benefit by using replication-deficient vectors. The viral vectors are engineered to be unable to replicate in normal cells, ensuring safety while maintaining efficient gene silencing through the delivered shRNA. This approach turns the vector's replicative capability into a controlled feature that enhances delivery without causing harmful replication.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach effectively inhibits cancer cell growth, tumorigenicity, and metastasis by selectively targeting Nanog or NanogP8, demonstrating significant reduction in tumor formation and metastatic potential in preclinical models, offering a promising therapeutic strategy for CRC.
Implementation Method 1
an inhibitory RNA molecule, comprising an oligonucleotide that knocks down expression of either Nanog or NanogP8
Data Source
AI summary
The present description relates to an inhibitory RNA molecule, comprising an oligonucleotide that selectively knocks down expression a Nanog pseudogene expressed in many human cancers, a replicating viral vector capable of encoding such inhibitory RNA molecule, pharmaceutical compositions comprising said vector, and methods of treating cancer by administration of said pharmaceutical composition.